Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease typically causing death
within three years. Understanding the impact of disease on patients using health utility at …

Abstract Background The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised
(ALSFRS-R) is the preferred measure of health outcome in clinical trials in motor neuron …

We developed a preference‐based measure, the Amyotrophic Lateral Sclerosis Utility Index
(ALSUI), allowing computation of US population‐based utility weights for the wide range of …

Objectives: Amyotrophic lateral sclerosis (ALS) is a devastating disease that has serious
consequences in terms of impairments and disabilities, which are expected to impact on …

Background Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder.
Consequently, patients undergo a multidisciplinary treatment that often requires intensive …

Background The study aimed to appraise the health-related quality of life (HRQoL)
measured by the five-level EuroQol-5 dimensions (EQ-5D-5L) in amyotrophic lateral …

Aims To estimate the health utilities and quality-adjusted life years (QALYs) in patients with
amyotrophic lateral sclerosis (ALS) receiving reldesemtiv versus placebo in FORTITUDE …

Background: Amyotrophic lateral sclerosis (ALS) shows considerable clinical heterogeneity,
which affects clinical trials. A clinical staging system has been proposed for ALS with …

Background Amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) has
emerged as a clinical prognostic marker for clinical and research purposes in amyotrophic …

This study reports the results of a long-term economic evaluation of riluzole in the treatment
of amyotrophic lateral sclerosis (ALS) versus best supportive care in the United Kingdom …